European PRAC concludes Zynteglo (betibeglogene autotemcel) does not cause acute myeloid leukaemia

Review of two cases of AML in patients treated with investigation medicine, bb1111, found that the viral vector used by both medicines, was unlikely to be the cause. More plausible explanations include conditioning treatments and higher risk of blood cancer in sickle cell disease

SPS commentary:

The PRAC has also updated its recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.

Source:

European Medicines Agency